Pre-Clinical Study of a Novel Recombinant Botulinum Neurotoxin Derivative Engineered for Improved Safety

Cyto-012 is a recombinant derivative of Botulinum neurotoxin Type A (BoNT/A). It primarily differs from wild type (wt) BoNT/A1 in that it incorporates two amino acid substitutions in the catalytic domain of the light chain (LC) metalloprotease (E(224) > A and Y(366) > A), designed to provide a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vazquez-Cintron, Edwin, Tenezaca, Luis, Angeles, Christopher, Syngkon, Aurelia, Liublinska, Victoria, Ichtchenko, Konstantin, Band, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971498/
https://www.ncbi.nlm.nih.gov/pubmed/27484492
http://dx.doi.org/10.1038/srep30429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971498/
https://www.ncbi.nlm.nih.gov/pubmed/27484492
http://dx.doi.org/10.1038/srep30429

Ejemplares similares